The value of pharmacogenetic markers for personalized approach to the statins treatment
Abstract
This review presents the most studied genetic markers which are risk factors for adverse drug reactions in patients who are treated with statins and/or associated with resistance to them. We have considered the possible practical advice for individual therapy with statins in patients with a known genotype. Identification of the gene variant SLCO1B1*5 is a risk factor for myopathy and rhabdomyolysis and HMGCR gene haplotype H7 is associated with less reduction in LDL cholesterol in patients receiving statins. Pathological effect of a particular genetic marker is modified by statin class or calculated personal dose. The use of pharmacogenetic testing will reduce the frequency of adverse outcomes of statins and make a prediction their performance in a specific patient. Howeverfurther studies on the translation of these personalized medicine tests to clinical practice are needed.
About the Authors
N. V. Kokh
1nstitute of Chemical Biology and Fundamental Medicine SB RAS
Russian Federation
Russian Federation
G. I. Lifshits
1nstitute of Chemical Biology and Fundamental Medicine SB RAS; Novosibirsk National Research State University
Russian Federation
Russian Federation
References
1. Государственный реестр лекарственных средств [Электронный ресурс]. - Режим доступа: http://www.grls.rosminzdrav.ru.
2. Петров В.И., Смусева О.Н., Соловкина Ю.В. и др. Оценка безопасности терапии статинами у больных с ишемической болезнью сердца // Вестник СевероЗападного государственного медицинского университета им. И.И. Мечникова. - 2012. - Т.4, № 2. - С. 76-79.
3. Abe T., Kakyo M., Tokui T. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1 // J. Biol. Chem. - 1999. -Vol. 274 (24). - P. 17159-17163.
4. Arora R.M. Liebo F. Maldonado satin-induced myopathy: the two faces of Janus // J. Cardiovasc. Pharmac. Therap. - 2006. - Vol. 11 (2). - P. 105-112.
5. Ballantyne C.M., Corsini A., Davidson M. Risk for myopathy with statin therapy in high-risk patients // Arch. Intern. Med. - 2003. - Vol. 63. - P. 553-564.
6. Bays H. Statin safety: an overview and assessment of the data // Am. J. Card. - 2006. - Vol. 97. - P. S6-S26.
7. Brunham L.R., Lansberg P.J., Zhang L. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. // Pharma-cogenomics J. - 2012. - Vol. 12 (3). - P. 233-240.
8. Chasman D.I., Posada D., Subrahmanyan L. et al. Pharmacogenetic study of statin therapy and cholesterol reduction // JAMA. - 2004 - Vol. 292 (11). - P. 1302.
9. Colhoun H.M., Betteridge D.J., Durrington P.N. et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Ator-vastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial // Lancet. - 2004. - Vol. 364. -P. 685-696.
10. Donnelly L.A., Doney A.S., Dannfald J. et al. A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study // Pharmacogenet. Genomics. - 2008. - Vol. 18. - P. 1021-1026.
11. Downs J.R., Clearfield M., Weis S. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels // JAMA. - 1998. - Vol. 279. - P. 1615-1622.
12. Giacomini K.M., Balimane P.V., Cho S.K. International transporter consortium commentary on clinically important transporter polymorphisms // Clin. Pharmacol. Ther. - 2013 - Vol. 94 (1). -P. 23-29.
13. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial // Lancet. - 2002. -Vol. 360.
14. Kalliokoski A., Neuvonen M., Neuvonen P.J. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide // J. Clin. Pharmacol. - 2008 - Vol. 48 (3).
15. Keskitalo J.E., Zolk O., Fromm M.F., Kurkinen K.J. et al. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin // Clin. Pharmacol. Ther. - 2009 - Vol. 86 (2). - P. 197-203.
16. Krauss R.M., Mangravite L.M. et al. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low density lipoprotein cholesterol response to simvastatin treatment // Circulation. - 2008. - Vol. 117. - P. 1537-1544.
17. Lindgren V., Luskey K.L. et al. Human genes involved in cholesterol metabolism: chromosomal mapping of the loci for the low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl-coenzyme A reductase with cDNA probes // Proc. Natl. Acad. Sci. USA. - 1985. -Vol. 82. - P. 8567-8571.
18. Maeda K., Ieiri I., Yasuda K., Fujino A. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and te-mocapril // Clin. Pharmacol. Ther. - 2006. - Vol. 79 (5). -P. 427-439.
19. PharmGKB. База данных по фармакогеномике [Электронный ресурс]. - Режим доступа: https://www. pharmgkb.org.
20. Saks F.M., Pfeffer M.A., Moye L.A. et al. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels // N. Engl. J. Med. - 1996. -Vol. 335. - P. 1001-1009.
21. Schuster H. The GALAXY Program an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Investigating cardiovascular risk reduction - the Rosuvastatin GALAXY Programme // Expert Rev. Cardiovasc. Ther. - 2007. -Vol. 5. - P. 177-193.
22. Search Collaborative Group. SLCO1B1 variants and statin-induced myopathy - a genomewide study // N. Engl. J. Med. - 2008. - Vol. 359 (8). - P. 789-799.
23. Sever P.S., Dahlof B., Poulter N.R. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial // Lancet. -2003. - Vol. 361. - P. 1149-1158.
24. Shepherd J., Cobbe S.M., Ford I. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia // N. Engl. J. Med. - 1995. -Vol. 333. - P. 1301-1307.
25. Spatz E.S., Canavan M.E., Desai M.M. From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey / / Circulation: Cardiovascular Quality and Outcomes. - 2009. - Vol. 2. - P. 41-48.
26. The long-term intervention with pravastatin in ischaemic disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels // N. Engl. J. Med. - 1998. - Vol. 339. -P. 1349-1357.
27. Voora D., Shah S.H., Reed C.R. Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response // Circ. Cardiovasc. Genet. - 2008. - Vol. 1 (2). - P. 100-106.
28. Whirl-Carrillo M. et al. Pharmacogenomics knowledge for personalized medicine // Clin. Pharmac. Therap. - 2012. - Vol. 92 (4). - P. 414-417.
29. Zuccaro P., Mombelli G., Calabresi L. Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin Pharmacological research // Offic. J. Ital. Pharmacol. Soc. - 2007. -Vol. 55 (4). -P. 310-317.
Review
For citations:
Kokh N.V., Lifshits G.I. The value of pharmacogenetic markers for personalized approach to the statins treatment. Acta Biomedica Scientifica. 2013;(5):176-180. (In Russ.)
Views:
405
Email this article 
